During their hospitalization, 43% of patients with diabetes received metformin, 22.7% received a DPP4 inhibitor, 18.8% received a sulfonylurea, 18.1% received insulin, 1.9% received an SGLT2 inhibitor and 0.1% received a GLP1 receptor agonist (Table 1). The gene discussed is INS; the disease is diabetes mellitus.